Drug & supplement interaction

Lacticaseibacillus Rhamnosus + Elosulfase Alfa

Elosulfase Alfa brand name: Vimizim.

No Known Interaction

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated July 2026 · Pair last verified Sep 13, 2026

The bottom line No known interaction

We found no known interaction between Lacticaseibacillus Rhamnosus and Elosulfase Alfa in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first.

Know someone taking this? Share

Facebook Post Reddit Email

On this page

Interaction report

Lacticaseibacillus Rhamnosus and Elosulfase Alfa

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Elosulfase Alfa and Lacticaseibacillus Rhamnosus in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Lacticaseibacillus Rhamnosus safety at a glance

Lacticaseibacillus... overall Generally safe Generally well tolerated in healthy people, though serious infections have rarely occurred in very ill or immunocompromised individuals.

Pregnancy Possibly Safe When used orally and appropriately. Lacticaseibacillus rhamnosus GG has been used with apparent safety starting 2-4 weeks before delivery. L. rhamnosus HN001 ha... Read the full pregnancy detail

Breastfeeding Possibly Safe When used orally and appropriately. Lacticaseibacillus rhamnosus GG has been used with apparent safety when breastfeeding for up to six months and L. rhamnosus... Read the full breastfeeding detail

Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center) — the full detail is in the Special populations card below. Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Elosulfase Alfa and Lacticaseibacillus Rhamnosus? Ask Dr. Brian Staiger, PharmD, BCPS directly ›

Keep it in perspective

Lacticaseibacillus Rhamnosus Does Interact With Other Medications

Lacticaseibacillus Rhamnosus has 182 moderate known drug interactions in our database — Elosulfase Alfa isn’t one of them. If you take anything else, check it against the full list below.

Moderate 182 No known interaction 2,648 (incl. Elosulfase Alfa)

Taking anything else?

Check Another of Your Medications Against Lacticaseibacillus Rhamnosus

Covers the 2,830 medications we’ve checked against Lacticaseibacillus Rhamnosus. Pick one to open its full report.

What to actually watch for

What Lacticaseibacillus Rhamnosus Itself Has Been Linked To

This is not an interaction — nothing below involves Elosulfase Alfa. It is the side-effect record for Lacticaseibacillus Rhamnosus on its own, from the licensed Natural Medicines monograph. If something new turns up after you add Lacticaseibacillus Rhamnosus, this list is the first place to look. One entry is worth acting on rather than waiting out — marked below.

A higher chance of infection Worth acting on Additional detail
“Since Lacticaseibacillus rhamnosus preparations contain live and active microorganisms, there is some concern that they might cause pathological infection in some patients. Some lactobacilli species have been isolated in some cases of bacteremia, sepsis, splenic abscess, endocarditis, necrotizing fasciitis, pancreatic necrosis, and meningoencephalitis.”

Lacticaseibacillus Rhamnosus · Natural Medicines adverse-effect record, reported in antibiotic-associated diarrhea.
6 sources cited

4380. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. PubMed

4390. Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:

4391. Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. PubMed

4398. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.

8561. MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7. PubMed

13008. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
Mouth irritation or sores Additional detail
“Orally, taking Lacticaseibacillus rhamnosus alone or in combination with other probiotics may cause gastrointestinal side effects including diarrhea; however, these events are uncommon. In one small clinical study in infants with suspected cow's milk allergy who were receiving extensively hydrolyzed whey formula, diarrhea occurred in 5 of 13 infants receiving non-viable, heat-killed L.”

Lacticaseibacillus Rhamnosus · Natural Medicines adverse-effect record, reported in allergic rhinitis (hay fever).
3 sources cited

90235. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI

107528. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223-7. DOI

112506. Ishihara Y, Kanda J, Tanaka K, et al. Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. Int J Hematol 2014;100(6):607-10. PubMed
Diarrhea Additional detail

Recorded for Lacticaseibacillus Rhamnosus in the same Natural Medicines adverse-effect record shown under Mouth irritation or sores above.

Everything above comes from the Natural Medicines adverse-effect record for Lacticaseibacillus Rhamnosus — expand a row for the licensed statement it rests on. We haven’t matched Elosulfase Alfa to its FDA label in our system yet, so we can’t compare its own side-effect list here — the leaflet that comes with your prescription is the authoritative list for Elosulfase Alfa.

Special populations

Lacticaseibacillus Rhamnosus in Pregnancy & Breastfeeding

Pregnancy Possibly Safe

When used orally and appropriately. Lacticaseibacillus rhamnosus GG has been used with apparent safety starting 2-4 weeks before delivery. L. rhamnosus HN001 has been used from 14-16 weeks' gestation until 6 months post-delivery. The combination of L. rhamnosus with Bifidobacterium longum has been used from 2 months prior to delivery until 2 months after delivery or throughout pregnancy. The combination of L. rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 has been used for up to two trimesters during pregnancy. A combination of L. rhamnosus, Lactobacillus jensenii, Lactobacillus crispatus, and Lactobacillus gasseri has been used safely for 3-4 weeks from 32-36 weeks' gestation. A meta-analysis of four clinical trials shows that taking probiotics during pregnancy increases the relative risk of pre-eclampsia by 85% when compared with placebo. Although the specific effects of L. rhamnosus are unclear from this analysis, two of the included studies used L. rhamnosus GG and one used L. rhamnosus HN001. More information is needed to determine if certain patients are at increased risk.

Lactation Possibly Safe

When used orally and appropriately. Lacticaseibacillus rhamnosus GG has been used with apparent safety when breastfeeding for up to six months and L. rhamnosus HN001 has been used from 14-16 weeks' gestation until 6 months post-delivery. A combination of L. rhamnosus and Bifidobacterium longum has been used with apparent safety from 2 months prior to delivery until 2 months after delivery.

DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.© 2026 Therapeutic Research Center

How much people look this up

Where Lacticaseibacillus Rhamnosus and Elosulfase Alfa Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Lacticaseibacillus Rhamnosus

Steady interest

#1,004 of 1,452 supplements looked up here in the last 7 days

29 days ago today

Medication Elosulfase Alfa

Steady interest

#1,865 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?

Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Lacticaseibacillus Rhamnosus reference on this page ↓
Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Lacticaseibacillus Rhamnosus and Elosulfase Alfa records this page draws on were last updated July 11, 2026.
What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.

Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD, BCPS.

Supplement

About Lacticaseibacillus Rhamnosus

What is Lacticaseibacillus Rhamnosus?

Diarrhea (including antibiotic-related)
Digestive health
Vaginal and urinary health
Eczema and allergy prevention in children
Immune support

Lacticaseibacillus rhamnosus (often labeled L. rhamnosus GG) is a well-studied probiotic bacterium used mainly for diarrhea and general gut health. It is considered safe for most healthy people, with the best evidence for preventing certain types of diarrhea, but benefits for many other uses are uncertain. People who are seriously ill or have weakened immune systems should check with a doctor first.

Lacticaseibacillus rhamnosus · Lactobacillaceae · Whole live bacteria (probiotic strain) · Capsules, tablets, powders, sachets, drops, fermented dairy products (yogurt, kefir)

An interaction check asks whether these two react with each other — it does not ask whether Lacticaseibacillus Rhamnosus is a good idea for someone in your situation. Here is what our Lacticaseibacillus Rhamnosus record says about it on its own.

Lacticaseibacillus Rhamnosus: dosing

There is no single official dose for L. rhamnosus. Probiotic doses are usually measured in colony-forming units (CFU), and the amount used in studies varies widely by product and condition.The best approach is to follow the directions on the product label and choose a reputable brand. Because effects can depend on the specific strain, it helps to pick a product that lists the exact strain.

From our Lacticaseibacillus Rhamnosus monograph — the full record covers uses, side effects and every documented interaction.

Read the full Lacticaseibacillus Rhamnosus monograph & all interactions

Medication

About Elosulfase Alfa

Most-Reported Side Effects for Elosulfase Alfa

From FAERS, the FDA’s public side-effect reporting system (5,380 reports, all brands). Reports are voluntary and are not proof the drug caused the effect.

Fever 726 reports

Cough 344 reports

Vomiting 329 reports

Malaise 286 reports

Headache 258 reports

Keep checking

Other Drugs & Lacticaseibacillus Rhamnosus

Browse every other medication we’ve checked against Lacticaseibacillus Rhamnosus — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major

182Moderate

0Minor

2,647No known interaction

182 Moderate 2,647 No interaction

Moderate

182 interactions

Showing 60 of 182 moderate interactions — see all 182 on the Lacticaseibacillus Rhamnosus page.

No interaction 2,647 drugs checked — show the list

We also checked Lacticaseibacillus Rhamnosus against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,647 medications checked with no known interaction — see the full Lacticaseibacillus Rhamnosus list.

See the full Lacticaseibacillus Rhamnosus interactions page

See every supplement checked against Elosulfase Alfa, ranked by severity

Evidence & sources

Lacticaseibacillus Rhamnosus References

The 34 references that drive our Lacticaseibacillus Rhamnosus monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. PubMed
Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:
Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. PubMed
Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119-21. PubMed
Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079. PubMed
MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7. PubMed
Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80. PubMed
Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9. PubMed
Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017;117(6):804-813.
Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4. PubMed
Wickens K, Barthow C, Mitchell EA, et al. Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema. Pediatr Allergy Immunol. 2018 May;29(3):296-302.
Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020;127(2):275-284. PubMed
Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887. PubMed
Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
Farr A, Sustr V, Kiss H, et al. Oral probiotics to reduce vaginal group B streptococcal colonization in late pregnancy. Sci Rep. 2020;10(1):19745. PubMed
Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123. PubMed
Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915. PubMed
Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948. PubMed
Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
Davidson SJ, Barrett HL, Price SA, Callaway LK, Dekker Nitert M. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev. 2021;4(4):CD009951. PubMed
Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223-7. DOI
Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
Yefet E, Colodner R, Strauss M, Gam Ze Letova Y, Nachum Z. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm la
Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016;6(1):e25-9. PubMed
Rubin IMC, Stevnsborg L, Mollerup S, Petersen AM, Pinholt M. Bacteraemia caused by Lactobacillus rhamnosus given as a probiotic in a patient with a central venous catheter: a WGS case report. Infect Prev Pract 2022;4(1):100200. PubMed
Karime C, Barrios MS, Wiest NE, Stancampiano F. Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. BMJ Case Rep 2022;15(6):e249020.
Ishihara Y, Kanda J, Tanaka K, et al. Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. Int J Hematol 2014;100(6):607-10. PubMed
Sadowska-Krawczenko I, Paprzycka M, Korbal P, et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes. 2014;5(4):397-402. PubMed
Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38(4):457-8.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Lacticaseibacillus Rhamnosus and Elosulfase Alfa Together: Common Questions

Is it safe to take Lacticaseibacillus Rhamnosus with Elosulfase Alfa?

We do not list a known interaction between Lacticaseibacillus Rhamnosus and Elosulfase Alfa. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.

Does Lacticaseibacillus Rhamnosus interact with any other medications?

Yes. Lacticaseibacillus Rhamnosus has 182 documented drug interactions in our database — Elosulfase Alfa is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Lacticaseibacillus Rhamnosus monograph Uses, safety profile, and every drug interaction in one place Elosulfase Alfa supplement interactions Every supplement checked against Elosulfase Alfa, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 34 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Elosulfase Alfa and Lacticaseibacillus Rhamnosus?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.